VALUATION OF THE CT LI-RADS TREATMENT RESPONSE V2018 IN PATIENTS AFTER FIRST-LINE DEB-TACE) FOR HEPATOCELLULAR CARCINOMA (HCC)

Tóm tắt

Background: In hepatocellular carcinoma (HCC), locoregional therapy (LRT) included transarterial chemotherapy embolization - TACE is performed as a bridging or downstaging treatment, improved overall survival, or a curative treatment. Liver Imaging Reporting and Data Systems (LI-RADS) Treatment Response was created to evaluate each lesion post-TACE, which has localized and is suitable for determining whether the tumor is still viable or non-viable. Purpose: To evaluate the application of the Liver Imaging Reporting and Data System (LI-RADS) treatment response algorithm (LR-TR) on CT in patient post-treatment evaluation following drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC). Materials and Methods: Between 6/2021 and 9/2022, a prospective and retrospective cross-sectional study involved 29 patients with hepatocellular carcinoma (HCC) who underwent treatment-based drug-eluting beads transarterial chemoembolization (DEB-TACE). The clinical situation, AFP levels, and Computer tomography of the patient after treatment were analyzed.

Results: a total of 29 patients with a median age was 61,3 ± 11.03 years old, male to female ratio was 13.5 : 1. After first-line DEB-TACE: the performance status response were improved in 28/29 patient, AFP response in 31%, LR-TR non-viable in 13 (44.8%) of 29 patients. The performance status response- AFP response- imaging response correlation was not statistically different with p= 0.552 and p=0.647.

Conclusion: Using CT LR-TR to evaluate HCC post-DEB-TACE was an easy-to-use means, suitable for clinical practice, and useful for vascular interventionalist.